Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology

Tip Ranks
2025.11.14 15:25
portai
I'm PortAI, I can summarize articles.

Analyst Oliver McCammon from LifeSci Capital maintains a Buy rating on Aura Biosciences Inc., citing a promising pipeline and strategic expansion in ocular oncology. The company's bel-sar therapy shows potential in treating ocular oncology and bladder cancer. Positive Phase 3 trial results for choroidal melanoma are expected by Q4 2027. Aura's expansion into other ocular oncology indications aims to address a substantial market need, reinforcing growth potential. H.C. Wainwright also reiterated a Buy rating with a $22.00 price target.

Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, with a price target of $23.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Oliver McCammon has given his Buy rating due to a combination of factors that highlight the potential of Aura Biosciences Inc. The company’s promising pipeline, particularly their bel-sar therapy, is a significant factor. This therapy, designed to target cancer cells with a dual mechanism, shows potential in treating ocular oncology and bladder cancer. The upcoming Phase 3 trial results for choroidal melanoma, expected by Q4 2027, are anticipated to be positive, given the progress in patient enrollment and identification.
Additionally, Aura’s expansion into other ocular oncology indications suggests a strategic move to establish a strong franchise in this field. With an estimated 60,000 annual cases in the US and Europe, the company is positioned to address a substantial market need. The ongoing development and expected data from these additional indications in 2026 further reinforce the company’s growth potential, justifying the Buy rating.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.